Isofol announces the launch of new Advisory Board in connection with ASCO 2025
GOTHENBURG, Sweden, June 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company is participating in the yearly scientific conference ASCO in Chicago, US, and in connection with this, held an Advisory Board meeting gathering the company’s scientific advisors.
The information in the press release is intended for investors.
Isofol participates in the yearly conference of the American Society of Clinical Oncology (ASCO) held in Chicago, USA, between May 30 and June 3. ASCO is a world-leading oncology conference aiming to spread scientific findings to physicians and researchers within the field of oncology treatment, setting the agenda for future treatments.
In connection to the visit in Chicago, the inaugural meeting was held with Isofol’s newly established Advisory Board, consisting of Dr. Takayuki Yoshino, chairman of the Japan Society of Clinical Oncology; Prof. Heinz-Josef Lenz, USC Norris Comprehensive Cancer Center & Kerck School of Medicine, U.S.; and Prof. Sebastian Stintzing, Charité Universitätsmedizin – Berlin, Germany and study coordinator of the ongoing phase Ib/II trial. At the meeting, the advisors discussed the global development program, preparations for the previously announced Pre-IND-meeting with the U.S. Food and Drug Administration (FDA) as well as the Japanese equivalent PMDA.
“ASCO brings together the most prominent cancer experts in the world, an excellent platform to launch our new advisory board. I am particularly pleased that these high-profile experts have chosen to collaborate with us – all are global leaders in their field and their support is highly valuable to Isofol,” says Petter Segelman Lindqvist, CEO of Isofol.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST, on June 3, 2025.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that are expected to optimize the effect of the drug candidate.
Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com